Revolution Medicines Seeing Enthusiasm for Rasonque Launch, RBC Says

11:16 AM EDT, 10/14/2026 (MT Newswires) -- Revolution Medicines (RVMD) is seeing enthusiasm for the launch of Rasonque, which was approved by the US Food and Drug Administration in August for pancreatic cancer treatment, RBC Capital Markets said in a Wednesday note. The enthusiasm aligns with feedback from RBC's industry experts, according to the note. Payer onboarding and driving documents for new prescriptions are significant early launch factors, but patients are already converting from the early access program, the brokerage noted. A strong launch could generate $36 million in Q3 revenue for Rasonque, RBC added. The investment firm also noted the rest of Revolution Medicines' product pipeline, with the company focused on finding combination therapies and moving to first-line treatments. RBC raised its price target on Revolution Medicines to $260 per share from $259, with an outperform rating. Price: 194.34, Change: +5.90, Percent Change: +3.13